JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication

Severe asthma

Inactive Indication

Asthma-Chronic Obstructive Pulmonary Disease Overlap SyndromePulmonary Disease, Chronic Obstructive

Originator Organization

Vectura Group Ltd.

Active Organization

Kinaset Therapeutics, Inc.

Inactive Organization

Vectura Group Ltd.

License Organization

Vectura Group Ltd.

Kinaset Therapeutics, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC22H21N7O2

InChIKeyASOKEXGIQLZRHH-HNNXBMFYSA-N

CAS Registry1299417-07-4

Clinical Trials associated with Frevecitinib

NCT07532265

/ RecruitingPhase 2

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Start Date16 Jul 2026

Sponsor / Collaborator

Kinaset Therapeutics, Inc.

NCT05006521

/ CompletedPhase 1

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma; Part 3 is a repeat dose in patients with moderate to severe asthma and Part 4 is a repeat dose in patients with COPD.

Start Date30 Jul 2021

Sponsor / Collaborator

Kinaset Therapeutics, Inc.

NCT02740049

/ CompletedEarly Phase 1IIT

In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma

Asthma is a long term disease of the lungs. In asthma patients the sensitive airway tubes narrow in reaction to something that irritates the airways such as allergens or environmental pollutants. There is currently no cure for asthma and new medicines or combinations of medicines are needed that will be of benefit to patients particularly those with a more severe disease.
Activation of certain signal molecules inside the lung cells may participate in the development of asthma and the response to allergens. Blocking these signal molecules specifically with medicines might therefore be beneficial in the treatment of asthma. In this study we want to test a new medicine that specifically targets a subset of signal molecules that are associated with the allergen response in the lung. In particular, we want to test this medicine on cells obtained from the lungs of asthma patients. Understanding the effects of this new medicine on these asthmatic lung cells will give vital information on how this new medicine works before we can test it in asthma patients.

Start Date27 Jan 2016

Sponsor / Collaborator

Imperial College London

[+1]

100 Clinical Results associated with Frevecitinib

100 Translational Medicine associated with Frevecitinib

100 Patents (Medical) associated with Frevecitinib

Literatures (Medical) associated with Frevecitinib

01 Sep 2010·Eksperimental'naia i klinicheskaia farmakologiia

[Antiproliferative and antioxidant activity of new dihydroquercetin derivatives].

Article

Author: Matiushin, A I ; Nifant'ev, E E ; Semeĭkin, A V ; Koroteev, M P ; Rogovskiĭ, V S ; Kukhareva, T S ; Koroteev, A M ; Shimanovskiĭ, N L

Effect of nine new derivatives of dihydroquercetin (taxifolin) on the viability of cultivated normal and tumor cells, their antioxidant activity, and interconnection of the antioxidant activity with the chemical structure have been studied. Among these dihydroquercetin derivatives, the maximum antiproliferative activity on the model of rat fibroblast culture exhibited KN-2, KN-4, KN-7, and KN-8 compounds, while KN-7 and KN-8 compounds also showed maximum activity on the model of MCF-7 tumor cell culture (human breast cancer). The maximum general antioxidant activity was observed for the native dihydroquercetin and KN-8 compound. There is a strong correlation (with a correlation coefficient of 0.93) between the antiproliferative effects of dihydroquercetin derivatives on murine skin fibroblasts and MCF-7 cells (human breast cancer).

01 Jan 1999·Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases

Analysis of Prevalent Orientia tsutsugamushi in Aichi Prefecture

Article

Author: Kasuya, S ; Morishita, T ; Yamashita, T ; Tsuzuki, H ; Sakae, K ; Suzuki, Y ; Kadosaka, T

Orientia tsutsugamushi was isolated from one of 8 patients' sera in Aichi Prefecture, and was identified to have the same antigenicity with the KN-2 strain (KN-2 like) based on the reactivity with 13 types of strain-specific or cross-reactive monoclonal antibodies to Karp, Gilliam, and Kato strains. Four isolates from 4 unfed larvae and adult of Leptotrombidium pallidum were also classified as the KN-3 like strains. Using indirect immunofluorescence, sera from 20 patients with tsutsugamushi disease were tested for reactivity with KN-1, KN-2, KN-3, and GJ-1 strains, isolated from patients in Gifu Prefecture. Fifteen sera showed the highest titer against KN-2 strain in Immunogloburin M (IgM). Of the other 5, three were higher for KN-3 strain in IgM, and two were KN-1 or GJ-1, respectively. These results suggested that KN-2 like strains were prevalent in the region where the number of patients has been ranked the highest in Aichi Prefecture. KN-1, KN-3, and GJ-1 like strains were also existed in this area. KN-3 like strain was likely to be distributed in another area. Aichi Prefecture.

01 Nov 1994·Journal of clinical microbiologyQ2 · MEDICINE

Transmission of Rickettsia tsutsugamushi strains among humans, wild rodents, and trombiculid mites in an area of Japan in which tsutsugamushi disease is newly endemic

Q2 · MEDICINE

Article

Author: Yamashita, T ; Nagano, I ; Kang, J S ; Noda, N ; Kasuya, S

Thirty-two newly isolated strains of Rickettsia tsutsugamushi, 14 from patients with tsutsugamushi disease, 12 from wild rodents, and 6 from trombiculid mites parasitizing rodents in Gifu Prefecture, Japan, were examined for reactivities to 12 monoclonal antibodies by an indirect fluorescent-antibody test to classify their antigenicities. All of the isolates could be classified into one of six groups (KN-1, KN-2, KN-3, GJ-1, R158, and R161) according to their reactivities to the monoclonal antibodies. The KN-1 and GJ-1 strains that are prevalent among patients from Gifu Prefecture had the same reactivities as the Kawasaki and Kuroki strains, respectively, which have been isolated and are prevalent in the Miyazaki and Kagoshima prefectures in southwest Japan. The isolates from patients were different in serotype from those from rodents and mites (Leptotrombidium pallidum). The KN-2 and KN-3 strains were most prevalent among patients and among rodents and mites, respectively. No close similarity between KN-2 and other strains tested was observed. KN-3 is only a minor contributor to diseases in patients in Gifu Prefecture; however, it was proven that the same strain was prevalent in Niigata Prefecture in northern Japan. Thus, Gifu Prefecture is an area where southern, northern, and local strains are found. We hypothesize that humans are prone to infection with KN-2, GJ-1 (very similar to Kuroki), and KN-1 (very similar to Kawasaki), probably by infestation with Leptotrombidium scutellare. While both L. scutellare and L. pallidum parasitize wild rodents and may carry any rickettsial strain, the most virulent strain, KN-3, is predominant among wild rodents. Antigenic analysis using monoclonal antibodies to R. tsutsugamushi should be useful for epidemiological studies of infection with this organism.

News (Medical) associated with Frevecitinib

20 Jul 2026

·www.biospace.com

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

Dose-ranging study evaluating potential first- and best-in-class inhaled pan-JAK inhibitor in patients receiving medium-to-high dose ICS/LABA therapy BOSTON--(BUSINESS WIRE)-- Kinaset Therapeutics , a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced the first patient has been dosed in its Phase 2b clinical trial evaluating frevecitinib, a novel inhaled pan JAK inhibitor, in patients with severe asthma inadequately controlled despite treatment with medium-to-high dose inhaled corticosteroid long-acting beta agonist (ICS/LABA) therapy. PANAIRAMA is a randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate the efficacy, safety and pharmacokinetics of three doses of frevecitinib. The study is intended to identify the optimal dose regimen to support future pivotal clinical development. The trial will enroll patients across multiple clinical sites in the United States and internationally. Additional information about the PANAIRAMA study is available at ClinicalTrials.gov under identifier NCT07532265 . “The dosing of the first patient with frevecitinib represents an important step forward in its clinical development,” said Christopher O’Brien, MD, PhD, Chief Medical Officer of Kinaset Therapeutics. “Building on the strong foundation established by our Phase 1 program, we believe frevecitinib has the potential to be a first- and best-in-class inhaled therapy for patients whose asthma remains inadequately controlled with current treatment options. By targeting both Th2- and Th1-driven disease pathways, frevecitinib may address a broader population of patients and improve outcomes beyond current standards of care.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Asthma remains one of the most prevalent chronic respiratory diseases globally, and many patients continue to experience persistent symptoms, impaired lung function and exacerbations despite available maintenance therapies. Frevecitinib is the only inhaled pan-JAK inhibitor targeting JAK1, JAK2, JAK3 and TYK2 in clinical development. By delivering therapeutic concentrations directly to the lungs while limiting systemic exposure, frevecitinib has the potential to address multiple inflammatory pathways implicated in asthma, including Th2- and Th1-driven disease, and may offer a new treatment approach in patients with non-eosinophilic asthma who remain underserved by current therapies. In a prior Phase 1 study, frevecitinib demonstrated clinically meaningful reductions in fractional exhaled nitric oxide (FeNO), a biomarker of airway inflammation, in patients with mild asthma, moderate-to-severe asthma and chronic obstructive pulmonary disease (COPD). Frevecitinib also demonstrated dose-proportional pharmacokinetics with plasma levels remaining below pharmacologically active systemic concentrations, consistent with the absence of significant systemic or local safety concerns observed to date. About frevecitinib Frevecitinib is a novel, potential best-in-class inhaled pan-JAK inhibitor (JAK1, JAK2, JAK3, TYK2) that is being developed as a maintenance treatment for patients whose asthma remains inadequately controlled on standard inhaled therapies. With its broad mechanism of action, frevecitinib has the potential to address multiple inflammatory pathways implicated in asthma, including both Th2- and Th1-driven disease, and may help address an important limitation of existing treatment options. Frevecitinib was designed through an integrated chemistry and formulation strategy intended to overcome drug delivery challenges that have limited prior attempts to develop inhaled JAK inhibitors. The molecule is formulated as a dry powder for inhalation and is designed to deliver pharmacologically active concentrations directly to lung tissue while minimizing systematic exposure. Unlike other inhaled JAK inhibitor candidates, frevecitinib is intended to deliver therapeutic doses through a single actuation. About Kinaset Therapeutics, Inc. Kinaset Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel inhaled therapies for patients with severe respiratory diseases. The Company’s lead program, frevecitinib, is a differentiated inhaled pan-JAK inhibitor designed to deliver broad anti-inflammatory activity directly to the lungs while limiting systemic exposure. Frevecitinib is being developed for patients with serious respiratory conditions including asthma that remains inadequately controlled by standard inhaled maintenance therapies. For more information, visit the Company’s website . Contacts Company Contact Roger Heerman – Chief Business Officer info@kinasettx.com +1 (508) 858-5810 Media Contact LA Communications Lauren Arnold lauren@lacommunications.net +1 (617) 694-5387

30 Jun 2026

·www.biospace.com

Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair

Appointments add seasoned biotechnology, financial and governance expertise as company advances its frevecitinib Phase 2b in asthma program BOSTON--(BUSINESS WIRE)-- Kinaset Therapeutics , a clinical-stage biopharmaceutical company developing inhaled therapies for serious respiratory diseases, today announced the appointments of Daniel G. Welch as Chairman of its Board of Directors and David Lubner as an independent director and Chair of the Audit Committee. The appointments further strengthen Kinaset’s Board with proven biotechnology leadership, public company governance and financial expertise as the company advances frevecitinib, its lead inhaled pan-JAK inhibitor, through Phase 2b clinical development. The appointments follow Kinaset’s recently completed oversubscribed $103 million Series B financing, which is supporting the ongoing Phase 2b PANAIRAMA dose-ranging trial evaluating inhaled frevecitinib in patients with severe asthma inadequately controlled despite medium-to-high-dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) therapy. "Dan and David join the Board at an exciting and important time for Kinaset," said Robert Clarke, PhD, Chief Executive Officer of Kinaset Therapeutics. "Dan has successfully led biotechnology companies through clinical development, commercialization and value-creating strategic transactions, while David brings deep expertise in finance, capital markets, strategic transactions and corporate governance. Together, they add complementary experience that will be invaluable as we advance frevecitinib and position Kinaset for its next phase of clinical and corporate growth." Kinaset also announced that Thomas B. King, who has served as Chair of the Board since the company’s founding, will step down to pursue a new leadership opportunity. "Tom has played an instrumental role in Kinaset's growth from its founding through this important stage of development," Dr. Clarke said. "His leadership, strategic insight and steadfast commitment have helped position the company for success. On behalf of the Board and the entire Kinaset team, I thank Tom for his many contributions and wish him every success in his future endeavors." Mr. Welch brings more than 35 years of executive and board leadership experience across the biotechnology and pharmaceutical industries. He currently serves as Chairman of the Boards of Ultragenyx Pharmaceutical and Structure Therapeutics. Previously, he served as Chief Executive Officer of InterMune, where he led the development and commercialization of Esbriet before the company’s acquisition by Roche and as Chairman and Chief Executive Officer of Triangle Pharmaceuticals until its acquisition by Gilead Sciences. Mr. Welch has also served on the boards of numerous biotechnology companies, including Seagen (acquired by Pfizer), AveXis (acquired by Novartis), Hyperion Therapeutics (acquired by Horizon), Intercept Pharmaceuticals (acquired by AlfaSigma) and Nuvation Bio (acquired by AnHeart Therapeutics). "Frevecitinib has the potential to offer a differentiated treatment option for patients with severe inflammatory respiratory disease," said Mr. Welch. "The company has built meaningful momentum with the initiation of its Phase 2b trial, and I look forward to working closely with the Board and management team to help advance the program and realize its broader potential." Mr. Lubner is a seasoned life sciences finance executive with more than 25 years of experience in corporate finance, capital markets and strategic transactions. He previously served as Executive Vice President and Chief Financial Officer of Ra Pharma through its acquisition by UCB and has held senior financial leadership roles at Tetraphase Pharmaceuticals, PharMetrics and ProScript. He currently serves on the boards of Crescent Biopharma and Dyne Therapeutics and several private companies. Mr. Lubner previously served on the board of Arcellx Inc. (acquired by Gilead Sciences), Point Biopharma Inc. (acquired by Eli Lilly & Co.), Nightstar Therapeutics, Inc. (acquired by Biogen), Cargo Therapeutics, Inc., Vor Biopharma, Inc. and Therapeutics Acquisition Corp. "Kinaset has assembled an exceptional leadership team, a differentiated clinical program and a strong financial foundation," said Mr. Lubner. "I am excited to join the Board and look forward to helping guide the company through its next state of growth and value creation." About Kinaset Therapeutics, Inc. Kinaset Therapeutics is a clinical-stage biopharmaceutical company developing differentiated inhaled therapies for patients with severe respiratory diseases. The Company’s lead product candidate, frevecitinib, is an investigational inhaled pan-JAK inhibitor designed to provide broad anti-inflammatory activity directly in the lungs while minimizing systemic exposure. Frevecitinib is being developed to address significant unmet needs in severe respiratory diseases, including asthma that remains inadequately controlled despite standard inhaled maintenance therapies. For more information, visit . Contacts Company Contact Roger Heerman – Chief Business Officer info@kinasettx.com +1 (508) 858-5810 Media Contact LA Communications Lauren Arnold lauren@lacommunications.net +1 (617) 694-5387

Phase 2Executive ChangeAcquisition

12 Jan 2026

·endpoints.news

Kinaset rakes in $103M to advance inhaled asthma drug

Kinaset Therapeutics has scooped up $103 million in a Series B round, five years after emerging with $40 million and a plan to develop an inhaled drug for asthma. The biotech will use the fresh cash to put its only candidate, a pan-JAK inhibitor called frevecitinib, through mid-stage trials. It licensed the drug from Vectura, the once hotly-tipped inhaled drug developer that crashed when its own inhaled asthma therapy failed in Phase 3. Kinaset’s backers clearly believe it can defy this precedent. The oversubscribed fundraise was led by RA Capital Management and Forge Life Science Partners, with EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors and Sixty Degree Capital also contributing for the first time. Kinaset’s existing investors, Atlas Venture, 5AM Ventures and Gimv, also joined in. Henry Stusnick from RA Capital, Daniela Begolo from EQT and Peter Silverman from Forge have pulled up chairs at Kinaset’s board. Silverman was chief operating officer of Merus before its $8 billion acquisition by Genmab in September. Error: Survey not found. So far, clinical data on frevecitinib are sparse. In Phase 1, it cut asthma patients’ exhaled nitric oxide levels to “clinically relevant” levels, the company said a year or so ago (nitric oxide is a marker of airway inflammation). The planned mid-stage study will sign up patients with severe asthma that can’t be controlled by current inhaled therapies. The study should allow Kinaset to identify a dose for pivotal trials, the company said Saturday. CEO Robert Clarke said in the release that the JAK could work in asthma patients with a non-eosinophilic phenotype, “unlike the majority of existing therapeutics.” According to Kinaset’s website, frevecitinib is also in Phase 1 trials for COPD. Vectura is not the only company to have run into trouble developing a novel inhaled asthma product. Pieris Pharmaceuticals was hit badly when AstraZeneca walked away from an IL-4 receptor alpha inhibitor dubbed elarekibep in mid-2023.

Phase 1AcquisitionPhase 3

100 Deals associated with Frevecitinib

External Link

KEGG	Wiki	ATC	Drug Bank
D12993	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Severe asthma	Phase 2	United States	Kinaset Therapeutics, Inc.	16 Jul 2026
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome	Phase 1	United Kingdom	Kinaset Therapeutics, Inc.	30 Jul 2021
Pulmonary Disease, Chronic Obstructive	Phase 1	United Kingdom	Kinaset Therapeutics, Inc.	30 Jul 2021
Asthma	Phase 1	United Kingdom	Vectura Group Ltd.	27 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05006521 (Phase 1b, ATS2025)	Phase 3	Asthma	23	Frevecitinib 4 mg twice-daily	ufubsdtmkb(xwoorqbbbz) = hmgakdudxe aprvscycby (spmrkfjpvj ) View more	Positive	16 May 2025
NCT05006521 (Phase 1b, ATS2025)	Phase 3	Asthma	23	Placebo	swgofoggyn(vrgejaakmz) = wlktsghahf qrcaommszc (rtjtsvjxvx )	Positive	16 May 2025
NCT05006521 (ERS2024)	Phase 1	Pulmonary Disease, Chronic Obstructive	13	KN-002	fxhjpuirlb(aobcflputo) = xvdtvfpmdv fdiwwtoojw (fgqphadrjz ) View more	Positive	07 Sep 2024
NCT05006521 (ERS2024)	Phase 1	Pulmonary Disease, Chronic Obstructive	13	Placebo	fxhjpuirlb(aobcflputo) = nyfrbrmteh fdiwwtoojw (fgqphadrjz ) View more	Positive	07 Sep 2024
NCT05006521 (ERS2024)	Phase 1	Asthma	23	KN-002 4 mg BID	waaiipfwwm(zytuazahgn) = jyzcwoebcj ppuhauzlrs (xakykqojyk ) View more	Positive	07 Sep 2024
NCT05006521 (ERS2024)	Phase 1	Asthma	23	Placebo	waaiipfwwm(zytuazahgn) = qdcwrzfomw ppuhauzlrs (xakykqojyk ) View more	Positive	07 Sep 2024
NCT05006521 (ATS2024) Manual	Phase 1	Mild asthma	32	KN-002	tyeusrdxak(wzjeztivca) = No safety concerns were reported lvwngqqpjv (vpunqtjcgs ) View more	Positive	21 May 2024
NCT05006521 (AAAAI2024) Manual	Phase 1	Mild asthma eosinophilic \| non-eosinophilic	-	KN-002	jeyldmbcok(kicqdgmomc) = Overall, the most common AE was headache gpjmrjfkid (lqixzsgddi ) View more	Positive	23 Feb 2024
NCT02740049 (CTgov)	Early Phase 1	Asthma	9	VR588	ctupilgqkp(ljgqvmuvyd) = tptggpymit wfvthtcfcq (ibxswxedle, 319.7) View more	-	09 Oct 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis